277 related articles for article (PubMed ID: 32539551)
1. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
Lamberti G; Andrini E; Sisi M; Federico AD; Ricciuti B
Future Oncol; 2020 Aug; 16(23):1751-1766. PubMed ID: 32539551
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application.
Xie H; Wang W; Qi W; Jin W; Xia B
Front Immunol; 2021; 12():661115. PubMed ID: 34712221
[TBL] [Abstract][Full Text] [Related]
3. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
Huang JL; Chang YT; Hong ZY; Lin CS
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328658
[TBL] [Abstract][Full Text] [Related]
4. Diverse immune response of DNA damage repair-deficient tumors.
Qing T; Jun T; Lindblad KE; Lujambio A; Marczyk M; Pusztai L; Huang KL
Cell Rep Med; 2021 May; 2(5):100276. PubMed ID: 34095878
[TBL] [Abstract][Full Text] [Related]
5. The complementarity of DDR, nucleic acids and anti-tumour immunity.
Kornepati AVR; Rogers CM; Sung P; Curiel TJ
Nature; 2023 Jul; 619(7970):475-486. PubMed ID: 37468584
[TBL] [Abstract][Full Text] [Related]
6. Interfaces between cellular responses to DNA damage and cancer immunotherapy.
Pilger D; Seymour LW; Jackson SP
Genes Dev; 2021 May; 35(9-10):602-618. PubMed ID: 33888558
[TBL] [Abstract][Full Text] [Related]
7. Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy.
Ye Z; Shi Y; Lees-Miller SP; Tainer JA
Front Immunol; 2021; 12():797880. PubMed ID: 34970273
[TBL] [Abstract][Full Text] [Related]
8. Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.
Tian W; Shan B; Zhang Y; Ren Y; Liang S; Zhao J; Zhao Z; Wang G; Zhao X; Peng D; Bi R; Cai S; Bai Y; Wang H
Cancer Med; 2020 Mar; 9(6):2190-2200. PubMed ID: 31991061
[TBL] [Abstract][Full Text] [Related]
9. Targeting DNA damage response kinases in cancer therapy.
Gottifredi V
Mutat Res; 2020; 821():111725. PubMed ID: 33157476
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
11. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.
Arjumand W; Asiaf A; Ahmad ST
Methods Mol Biol; 2018; 1699():3-21. PubMed ID: 29086365
[TBL] [Abstract][Full Text] [Related]
12. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Gao D; Herman JG; Guo M
Oncotarget; 2016 Jun; 7(24):37331-37346. PubMed ID: 26967246
[TBL] [Abstract][Full Text] [Related]
13. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy.
Nowsheen S; Whitley AC; Yang ES
Curr Mol Med; 2012 Jul; 12(6):788-803. PubMed ID: 22292444
[TBL] [Abstract][Full Text] [Related]
15. DNA Damage Repair Deficiency in Prostate Cancer.
Burdak-Rothkamm S; Mansour WY; Rothkamm K
Trends Cancer; 2020 Nov; 6(11):974-984. PubMed ID: 32517958
[TBL] [Abstract][Full Text] [Related]
16. A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer.
Ding K; He Y; Wei J; Fu S; Wang J; Chen Z; Zhang H; Qu Y; Liang K; Gong X; Qiu L; Chen D; Xiao B; Du H
Front Immunol; 2022; 13():943090. PubMed ID: 36081518
[TBL] [Abstract][Full Text] [Related]
17. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C; Qin K; Lin A; Jiang A; Cheng Q; Liu Z; Zhang J; Luo P
J Exp Clin Cancer Res; 2022 Sep; 41(1):268. PubMed ID: 36071479
[TBL] [Abstract][Full Text] [Related]
18. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
Concannon K; Morris BB; Gay CM; Byers LA
Mol Cell; 2023 Mar; 83(5):660-680. PubMed ID: 36669489
[TBL] [Abstract][Full Text] [Related]
19. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Yap TA; Plummer R; Azad NS; Helleday T
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
[TBL] [Abstract][Full Text] [Related]
20. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
Swift SL; Lang SH; White H; Misso K; Kleijnen J; Quek RG
Future Oncol; 2019 Oct; 15(28):3283-3303. PubMed ID: 31535940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
